Clinical Trial Update: An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis [Phase 3]

View source ↗

Summary

Phase 3 trial results evaluating the efficacy and safety of guselkumab in palmoplantar pustulosis; the study is completed with results posted in 2019-02-21.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Palmoplantar Pustulosis

Drugs mentioned

• TREMFYA (guselkumab)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Palmoplantar Pustulosis | Phase 3 | Status: COMPLETED | Results posted: 2019-02-21